Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2-amplified biliary tract cancer (BTC) Meeting Abstract
| Authors: | Pant, S.; Fan, J.; Oh, D. Y.; Choi, H. J.; Kim, J. W.; Chang, H. M.; Bao, L.; Sun, H. C.; Macarulla Mercade, T.; Xie, F.; Metges, J. P.; Jieer, Y.; Bridgewater, J. A.; Tejani, M. A.; Chen, E. Y. S.; Wasan, H. S.; Ducreux, M. P.; Ma, J. F.; Garfin, P. M.; Harding, J. J. |
| Abstract Title: | Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2-amplified biliary tract cancer (BTC) |
| Meeting Title: | 2023 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2023 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-06-01 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.16_suppl.4008 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: 4008 -- This meeting was also held virtually -- Source: Cinahl |
